Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.